Collaborators
Sign in to add collaborator| Jonathan D. Dinman | collaborator | 1995-2001 | Rutgers - Robert Wood Johnson Medical School |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Bhattacharyya A, Trotta CR, Narasimhan J, et al. (2021) Small molecule splicing modifiers with systemic HTT-lowering activity. Nature Communications. 12: 7299 |
| Luban J, Sattler R, Mühlberger E, et al. (2020) The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines. Virus Research. 198246 |
| Luban J, Sattler R, Mühlberger E, et al. (2020) The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines. Biorxiv : the Preprint Server For Biology |
| Friesen WJ, Johnson B, Sierra J, et al. (2018) The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential. Plos One. 13: e0206158 |
| Cao L, Weetall M, Trotta C, et al. (2018) Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties. Molecular Cancer Therapeutics |
| McDonald CM, Campbell C, Torricelli RE, et al. (2017) Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England) |
| Friesen WJ, Trotta CR, Tomizawa Y, et al. (2017) The nucleoside analog clitocine is a potent and efficacious readthrough agent. Rna (New York, N.Y.) |
| Cao L, Branstrom A, Baird J, et al. (2017) PTC299 Is a Novel DHODH Inhibitor That Modulates VEGFA mRNA Translation and Inhibits Proliferation of a Broad Range of Leukemia Cells Blood. 130: 1371-1371 |
| Cao L, Weetall M, Bombard J, et al. (2016) Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform. Plos One. 11: e0168366 |
| Weetall M, Davis T, Elfring G, et al. (2016) Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein Translation. Clinical Pharmacology in Drug Development. 5: 296-305 |